epidermal growth factor receptor tyrosine kinase inhibitor - Globe Thesis

Keyword [epidermal growth factor receptor tyrosine kinase inhibitor] Result: 41 - 60 \| Page: 3 of 4
41.	Analysis Of Clinical Effect And Gene Monitoring Of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor In The Treatment Of Advanced Non-small Cell Lung Cancer
42.	The Latest Progress Of Targeted Therapy Non-samll Cell Lung Cancer With Brain Metastases
43.	Docetaxel Plus Platinum Versus Pemetrexed Plus Platinum As Subsequent Treatment Of Advanced Lung Adenocarcinoma With Acquired Resistance To EGFR-TKI,Gefitinib
44.	Clinical Observation Of EGFR-TKIs Combined With WBRT Versus EGFR-TKIs Alone In The Treatment Of Patients With EGFR-sensitive Mutant Lung Adenocarcinoma With Inital Brain Metastases
45.	The Analysis Of Treatment Effect By Different Strategies For Advanced Lung Adenocarcinoma Patients With EGFR Sensitive Mutation Positive
46.	Clinical Study On The Influential Factors Of Aquired Resistance To EGFR-TKI And The Treatment Strategy After Drug Resistance In Non-small Cell Lung Cancer
47.	The Case Analysis Of Epidermal Growth Factor Receptor-targeted Therapies Combined With Chemoradiotherapy In Esophageal Squamous Cell Carcinoma And Literature Review
48.	Dynamic Monitoring Of Lymphocyte Subpopulation During The EGFR-TKI Therapy For Predicting The Efficacy And Resistance Of EGFR-TKI In EGFR Mutated Lung Cancer Patients
49.	Study On The Relationship Between The Expression Level Of MiR-221 In Peripheral Blood And The Acquired Resistance Of The First Generation Of EGFR-TKIs In Lung Cancer
50.	Influence Of TMB And TP53 Gene Mutation On The Efficacy Of Targeted Drugs In Patients With Advanced Lung Cancer Harboring EGFR-sensitive Mutations
51.	Experimental Study On EGFR-TKI Resistant Non-Small Cell Lung Cancer With Antiangiogenic Drugs
52.	Effect Of EGFR-TKI Treatment On The Prognosis Of Stage ? Lung Adenocarcinoma With Chronic Obstructive Pulmonary Disease With High Secretion Of Sputum And Mucus
53.	Study On TCM Syndromes And Correlation Of EGFR-TKIs Targeted Therapy In Patients With Advanced NSCLC
54.	Study On The Role Of MiR-873 In The Reversing Effect Of Intercalated Treatment In Lung Cancer Patients With Acquired Resistance To EGFR Tyrosine Kinase Inhibitors
55.	Study On Pharmacological Effects And Mechanism Of Dihydroartemisinin On Non-small Cell Lung Cancer
56.	Application Value Of EGFR Mutant Protein Expression In Targeted Therapy With Tyrosine Kinase Inhibitors In Advanced Lung Adenocarcinoma
57.	To Investigate The Effect And Mechanism Of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor On The Expression Of IL-6 In EGFR-mutant Lung Cancer Cell Lines
58.	Discussion Of Brain Radiotherapy In Patients With EGFR Mutant Lung Adenocarcinoma With Brain Metastasis Treated With EGFR-TKI
59.	Correlation Analysis Of Acquired EGFR T790M Mutation In Advanced Lung Adenocarcinoma
60.	Meta-analysis Of EGFR-TKIs Combined With Anti-vascular Targeting Drugs Versus EGFR-TKIs In The Treatment Of Advanced Non-small Cell Lung Cancer
<<First <Prev Next> Last>> Jump to